Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

NCT07343596 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Oral Cavity Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DEVICE: Patient-Specific Culture Vessel

Sponsor

University of Wisconsin, Madison